Cite
HARVARD Citation
Tweehuysen, L. et al. (2018). Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis & rheumatology. 70 (1), pp. 60-68. [Online].